OMCL Omnicell

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.
Company profile
Ticker
OMCL
Exchange
Website
CEO
Randall Lipps
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Apple • Dell • Super Micro Computer • Fitbit • Zepp Health • One Stop Systems • Socket Mobile • Sector 5 • Helo ...
Former names
OMNICELL COM /CA/, OMNICELL INC /CA/
SEC CIK
Corporate docs
IRS number
943166458
OMCL stock data
()
News
Stocks That Hit 52-Week Highs On Tuesday
2 Feb 21
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2021
2 Feb 21
10 Biggest Price Target Changes For Tuesday
2 Feb 21
Piper Sandler Upgrades Omnicell to Overweight, Raises Price Target to $147
2 Feb 21
Omnicell: Q4 Earnings Insights
1 Feb 21
Press releases
Omnicell Appoints Christine Mellon as Chief People Officer
22 Feb 21
Omnicell to Present at Upcoming Investor Conferences
12 Feb 21
Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer
8 Feb 21
Omnicell Reports Fiscal Year and Fourth Quarter 2020 Results
1 Feb 21
Omnicell, Inc. to Host Earnings Call
1 Feb 21
Calendar
24 Feb 21
28 Feb 21
31 Dec 21
Financial summary
Quarter (USD) |
Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) |
Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Financial data from Omnicell earnings reports.
Cash burn rate (estimated) | Burn method: Change in cash | Burn method: Operating income/loss | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 489.92M | 489.92M | 489.92M | 489.92M | 489.92M | 489.92M |
Cash burn (monthly) | 46.42M | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) | (positive/no burn) |
Cash used (since last report) | 91.66M | n/a | n/a | n/a | n/a | n/a |
Cash remaining | 398.26M | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | 8.6 | n/a | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Feb 21 | Randall A Lipps | Common Stock | Grant | Aquire A | No | No | 0 | 20,715 | 0 | 230,352 |
9 Feb 21 | Randall A Lipps | Common Stock | Grant | Aquire A | No | No | 0 | 20,715 | 0 | 186,116 |
9 Feb 21 | Dan S Johnston | Common Stock | Grant | Aquire A | No | No | 0 | 4,760 | 0 | 37,164 |
9 Feb 21 | Dan S Johnston | Common Stock | Grant | Aquire A | No | No | 0 | 5,675 | 0 | 32,405 |
9 Feb 21 | Scott Peter Seidelmann | Common Stock | Grant | Aquire A | No | No | 0 | 9,520 | 0 | 47,918 |
9 Feb 21 | Scott Peter Seidelmann | Common Stock | Grant | Aquire A | No | No | 0 | 11,350 | 0 | 38,398 |
9 Feb 21 | Peter J. Kuipers | Common Stock | Grant | Aquire A | No | No | 0 | 11,350 | 0 | 71,713 |
9 Feb 21 | Peter J. Kuipers | Common Stock | Grant | Aquire A | No | No | 0 | 9,520 | 0 | 60,363 |
Institutional ownership Q4 2020
13F holders |
Current |
---|---|
Total holders | 340 |
Opened positions | 75 |
Closed positions | 28 |
Increased positions | 86 |
Reduced positions | 135 |
13F shares |
Current |
---|---|
Total value | 10.85B |
Total shares | 42.49M |
Total puts | 13.4K |
Total calls | 66K |
Total put/call ratio | 0.2 |
Largest owners |
Shares | Value |
---|---|---|
BLK Blackrock | 6.66M | $799.7M |
Vanguard | 4.49M | $539.18M |
Wellington Management | 2.51M | $301.2M |
Conestoga Capital Advisors | 1.62M | $194.12M |
CS Credit Suisse | 1.36M | $162.64M |
STT State Street | 1.29M | $154.46M |
BK Bank Of New York Mellon | 1.16M | $138.74M |
Geneva Capital Management | 910.28K | $109.25M |
ArrowMark Colorado | 891.22K | $106.96M |
Dimensional Fund Advisors | 875.6K | $105.09M |
Financial report summary
?Competition
Cardinal Health • Cerner • Mckesson • Grifols SA - ADR - Level III • Tabula Rasa HealthCareRisks
- We face risks related to adverse public health epidemics, including the ongoing global COVID-19 pandemic, which had an adverse effect on and, depending on the severity and duration of the pandemic, could continue to adversely affect our business, financial condition, and results of operations.
- Unfavorable economic and market conditions and a decreased demand in the capital equipment market could adversely affect our operating results.
- We may fail to develop new solutions or enhance existing solutions to react to changes in technology and customer requirements in a timely and cost-effective manner, or our new or enhanced solutions may not achieve market acceptance.
- We operate in highly competitive markets, and we may be unable to compete successfully.
- We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial position.
- The transition to selling more products which include a software as a service or solution as a service subscription presents a number of risks.
- Delays in installations of our medication management automation solutions or our more complex medication packaging systems could harm our competitive position, results of operations, and financial condition.
- We are subject to laws, regulations, and other legal obligations related to privacy, data protection, and information security, and the costs of compliance with, and potential liability associated with, our actual or perceived failure to comply with such obligations could harm our business.
- If we experience a significant disruption in our information technology systems, breaches of data security, or cyber-attacks on our systems or solutions, our business could be adversely affected.
- We may fail to realize the potential benefits of acquired businesses, including the 340B Link Business, which could negatively affect our business, financial condition, and operating results.
- If goodwill or other intangible assets that we recorded in connection with the Aesynt, Ateb, InPharmics, and 340B Link Business acquisitions, or other prior acquisitions, become impaired, we could be required to take significant charges against earnings.
- The healthcare industry is subject to legislative and regulatory changes, as well as financial constraints and consolidation, which could adversely affect the demand for our products and services.
- Government regulation of the healthcare industry could reduce demand for our products, or substantially increase the cost to produce our products.
- Our international operations may subject us to additional risks that can adversely affect our operating results.
- Covenants in our A&R Credit Agreement restrict our business and operations in many ways, and if we do not effectively manage our compliance with these covenants, our financial conditions and results of operations could be adversely affected.
- Our success is dependent on our ability to recruit and retain skilled and motivated personnel.
- Our failure to protect our intellectual property rights could negatively affect our ability to compete.
- If we are unable to maintain our relationships with group purchasing organizations (“GPOs”) or other similar organizations, we may have difficulty selling our products and services to customers represented by these organizations.
- We depend on a limited number of suppliers for our products, and our business may suffer if we were required to change suppliers to obtain an adequate supply of components, equipment, and raw materials on a timely basis.
- The United Kingdom’s withdrawal from the European Union (“Brexit”) could adversely affect us.
- Our U.S. government lease agreements are subject to annual budget funding cycles and mandated unilateral changes, which may affect our ability to enter into such leases or to recognize revenues, and sell receivables based on these leases.
- If we fail to manage our inventory properly, our revenue, gross margin, and profitability could suffer.
- Intellectual property claims against us could harm our competitive position, results of operations, and financial condition.
- Product liability claims against us could harm our competitive position, results of operations, and financial condition.
- We are dependent on technologies provided by third-party vendors, the loss of which could negatively and materially affect our ability to market, sell, or distribute our products.
- The market price of our common stock may continue to be highly volatile.
- Our quarterly operating results may fluctuate and may cause our stock price to decline.
- Raising additional capital may cause dilution to our existing stockholders, restrict our operations or harm our business, financial condition, and results of operations.
- Certain provisions in our charter documents and under Delaware law may delay or prevent an acquisition of us and limit our stockholders’ ability to obtain a favorable judicial forum for certain disputes.
- Conversion of the Notes may dilute the ownership interest of our stockholders, depress the price of our common stock or, if the conditional conversion feature of the Notes is triggered, adversely affect our financial condition and operating results.
- The accounting method for convertible debt securities that may be settled in cash, such as the Notes, could have a material effect on our reported financial results.
- The convertible note hedge and warrant transactions may affect the value of our common stock.
- Changes in our tax rates, exposure to additional tax liabilities, or the adoption of new tax legislation could adversely affect our business and financial condition.
- Catastrophic events may disrupt our business and harm our operating results.
- Failure to maintain effective internal control over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could cause our stock price to decline.
Management Discussion
- Product revenues represented 71% and 74% of total revenues for the years ended December 31, 2020 and 2019, respectively. Product revenues decreased by $23.6 million, primarily due to the impact of the COVID-19 pandemic as health systems were focusing resources on COVID-19 essential activities during the second and third quarters of 2020.
- Services and other revenues represented 29% and 26% of total revenues for the years ended December 31, 2020 and 2019, respectively. Services and other revenues include revenues from technical services, SaaS, subscription software, and technology-enabled services, and other services. Services and other revenues increased by $18.8 million, primarily due to revenues of $10.2 million from the newly-acquired 340B Link Business, as well as continued growth in our installed customer base.
- Our international sales represented 11% and 10% of total revenues for the years ended December 31, 2020 and 2019, respectively, and are expected to be affected by foreign currency exchange rate fluctuations. We are unable to predict the extent to which revenues in future periods will be impacted by changes in foreign currency exchange rates.
Content analysis
?
Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abreast, accretion, agency, amplify, Apothecary, argument, ascertaining, attrition, BD, belonging, bench, biggest, bribery, BW, CareScheduler, carryback, certainty, characteristic, circumstance, clarifying, coaching, collaboration, confidence, confident, consecutive, correlated, Corrupt, corruption, coupon, creditor, curriculum, deep, DEI, disburse, disbursed, discrimination, downloaded, EBITDA, EnlivenHealth, entirety, epidemic, ESAT, ESG, ethically, expropriation, feature, feedback, foregoing, forfeited, Forfeiture, forum, fractional, fullest, fundamental, Glint, gradual, GSA, gym, healthy, heightening, hoc, identical, IFF, imputed, indenture, insignificant, insolvency, intuitive, issuable, journey, landscape, learning, lieu, lifestyle, main, mental, mission, navigate, nonlease, onset, Organisation, Orientation, outreach, pandemic, payroll, Pharmacotherapy, philosophy, Plano, play, proceeding, prohibited, protocol, PSGH, pursuit, redemption, reinventing, robust, rulemaking, satisfaction, score, secondary, segregated, seller, semiannually, Shield, sinking, social, sooner, split, strike, strong, sweep, talent, Teladoc, Township, transparency, trustee, turnover, unfair, uninsured, unmet, unsecured, unusual, unwinding, vaccination, vaccine, viability
Removed:
absorb, accredit, accredited, accuflex, add, adding, adjust, aesthetic, Affordable, AG, alike, alleged, Amerinet, Amortizing, Ann, approve, ARxIUM, attributable, bad, battery, Beijing, borrowed, Brewster, BriteSmile, cartfill, CenterTM, Centra, centralized, Cerner, characterized, closed, commerce, commonly, complementary, contingency, correct, Covidien, creating, decentralized, deem, delaying, demanding, Deployment, deposit, desire, detention, DIH, discouraging, discover, discovered, dispense, disrupted, disrupting, dissatisfied, doubtful, educating, elevate, eliminate, eliminating, enhancing, erode, Excellence, excessive, extremely, formal, frequent, Guardian, harmonize, heavily, hiring, hybrid, implementing, imprisonment, incumbent, instability, Intalere, integrity, intelligent, interfaced, interfacing, interoperate, introduced, inventorship, isolation, join, Jonathan, kls, KUKA, lack, Lancing, Lastly, legacy, licensure, managerial, Manchac, match, McIntire, McKesson, MedCarousel, membership, mindshare, minimizing, Nashville, newly, Ngo, Nhat, nurse, OmniCenter, oncology, OnDemand, outsourced, outsourcing, pace, penetration, Pittman, positioning, PPACA, practiced, preparing, preventing, prioritized, proposal, protecting, quantity, ramp, rapid, rebalanced, recording, recruiting, referenda, released, releasing, rent, repeal, replacing, replicate, reserve, restructure, Richmond, robopharma, rollout, Ruth, rx, SafetyStock, Science, Secretary, securing, sentiment, server, Shaw, shelf, show, simple, SinglePointe, Slovenia, solve, stabilize, Steuerungstechnik, stoppage, stratified, submitted, supplied, suremed, sustaining, Swisslog, symbiotic, Synergy, Tennessee, thirty, transmitted, Trieste, unclear, undetected, unemployment, uniformity, uniquely, unlawful, utilized, VBM, vehicle, Veteran, Virginia, Warner, WebsterCare, Willach, Yuyama
Financial reports
10-K
2020 FY
Annual report
24 Feb 21
10-Q
2020 Q3
Quarterly report
30 Oct 20
10-Q
2020 Q2
Quarterly report
31 Jul 20
10-Q
2020 Q1
Quarterly report
8 May 20
10-K
2019 FY
Annual report
26 Feb 20
10-Q
2019 Q3
Quarterly report
1 Nov 19
10-Q
2019 Q2
Quarterly report
2 Aug 19
10-Q
2019 Q1
Quarterly report
3 May 19
10-K
2018 FY
Annual report
27 Feb 19
10-Q
2018 Q3
Quarterly report
2 Nov 18
Current reports
8-K
Omnicell Reports Fiscal Year and Fourth Quarter 2020 Results
1 Feb 21
8-K
Departure of Directors or Certain Officers
26 Jan 21
8-K
Omnicell Announces Preliminary Fiscal Year 2020 Financial Results
13 Jan 21
8-K
Omnicell Reports Third Quarter 2020 Results
27 Oct 20
8-K
Omnicell Completes Acquisition of Pharmaceutical Strategy Group’s
1 Oct 20
8-K
Entry into a Material Definitive Agreement
25 Sep 20
8-K
Omnicell Announces Proposed Private Placement of $500 Million of Convertible Senior Notes
22 Sep 20
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12 Aug 20
8-K
Omnicell to Acquire Pharmaceutical Strategy Group’s
12 Aug 20
8-K
Omnicell Reports Second Quarter 2020 Results
28 Jul 20
Registration and prospectus
S-8
Registration of securities for employees
22 May 19
S-8
Registration of securities for employees
24 May 18
424B5
Prospectus supplement for primary offering
2 Nov 17
S-3ASR
Automatic shelf registration
2 Nov 17
S-8
Registration of securities for employees
1 Jul 15
S-8
Registration of securities for employees
29 Aug 13
S-8
Registration of securities for employees
7 Aug 11
S-8
Registration of securities for employees
28 May 09
S-8
Registration of securities for employees
16 Mar 08
424B5
Prospectus supplement for primary offering
23 May 07
Proxies
DEFA14A
Additional proxy soliciting materials
1 May 20
DEF 14A
Definitive proxy
7 Apr 20
DEF 14A
Definitive proxy
1 Apr 19
DEF 14A
Definitive proxy
1 Apr 18
DEF 14A
Definitive proxy
16 Apr 17
DEF 14A
Definitive proxy
17 Apr 16
DEF 14A
Definitive proxy
19 Apr 15
DEF 14A
Definitive proxy
20 Apr 14
DEF 14A
Definitive proxy
14 Apr 13
DEF 14A
Definitive proxy
11 Apr 12
Other
SD
Conflict minerals disclosure
27 May 20
SD
Conflict minerals disclosure
29 May 19
SD
Conflict minerals disclosure
29 May 18
UPLOAD
Letter from SEC
6 Jun 17
SD
Conflict minerals disclosure
30 May 17
CORRESP
Correspondence with SEC
18 May 17
UPLOAD
Letter from SEC
10 May 17
SD
Conflict minerals disclosure
26 May 16
SD
Conflict minerals disclosure
28 May 15
UPLOAD
Letter from SEC
22 Jul 14
Ownership
4
OMNICELL / Nhat H Ngo ownership change
18 Feb 21
4
OMNICELL / Scott Peter Seidelmann ownership change
11 Feb 21
4
OMNICELL / Peter J. Kuipers ownership change
11 Feb 21
4
OMNICELL / DAN S JOHNSTON ownership change
11 Feb 21
4
OMNICELL / RANDALL A LIPPS ownership change
11 Feb 21
SC 13G/A
OMNICELL / VANGUARD ownership change
9 Feb 21
SC 13G/A
OMNICELL / BlackRock ownership change
4 Feb 21
SC 13G/A
OMNICELL / WELLINGTON MANAGEMENT ownership change
11 Jan 21
4
OMNICELL / Robin Gene Seim ownership change
4 Jan 21
4
OMNICELL / Scott Peter Seidelmann ownership change
17 Dec 20
Patents
APP
Utility
Apparatuses, Systems, and Methods for Transporting Medications from a Central Pharmacy to a Patient In a Healthcare Facility
18 Feb 21
Provided herein are various apparatuses, systems, and methods for improving the efficiency of medication distribution within a healthcare facility.
APP
Utility
Medication Dispensing Cabinet Systems and Methods
28 Jan 21
A medication dispensing cabinet provides controlled access to medications and supplies stored in it.
GRANT
Utility
Storage cabinet with multiple RFID readers
4 Jan 21
An RFID cabinet system is provided for monitoring items having an RFID tag.
APP
Utility
Apparatuses, Systems, and Methods for the Automated Dispensing of and Packaging of Articles
30 Dec 20
Provided herein is a system for automated dispensing and packaging of articles.
GRANT
Utility
Apparatuses, systems, and methods for transporting medications from a central pharmacy to a patient in a healthcare facility
30 Nov 20
Provided herein are various apparatuses, systems, and methods for improving the efficiency of medication distribution within a healthcare facility.
Transcripts
2020 Q4
Earnings call transcript
2 Feb 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
28 Jul 20
2020 Q1
Earnings call transcript
9 May 20
2019 Q4
Earnings call transcript
6 Feb 20
2019 Q3
Earnings call transcript
24 Oct 19
2019 Q2
Earnings call transcript
25 Jul 19
2019 Q1
Earnings call transcript
26 Apr 19
2018 Q4
Earnings call transcript
7 Feb 19
2018 Q3
Earnings call transcript
25 Oct 18